Test Price
2,800 AED✅ Home Collection Available
KCNQ3 Gene Seizures, Benign Neonatal, Type 2 Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل جين KCNQ3 للنوبات الحميدة الوليدية من النوع الثاني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
يقدم هذا التحليل الجيني المتطور باستخدام تقنية التسلسل من الجيل التالي (NGS) دقة تشخيصية بنسبة 99.9% من خلال مختبر معتمد وفقًا لمعايير ISO 9001:2015. تضمن خدمة السحب المنزلي المتميزة نقل العينات بسلسلة تبريد معتمدة، مع جلسة استشارة وراثية شاملة قبل الفحص. الاستشارة الطبية عن بعد متاحة بعد صدور النتائج لتفسيرها سريريًا. للتحقق من تغطية التأمين، تواصل عبر واتساب على الرقم +971545488731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing & NGS validation.
- Premium Logistics: Paid Hospital-Grade Home Collection (8 AM–11 PM) with ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Post-test Telephonic Clinical Guidance for result interpretation by a DHA-licensed Neurologist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Comprehensive NGS Test for Benign Neonatal Seizures Type 2
This test analyzes the KCNQ3 gene using Next‑Generation Sequencing to confirm a diagnosis of benign familial neonatal seizures type 2 (BFNS2), a potassium channelopathy presenting in otherwise healthy newborns. The analysis covers all coding exons and splice‑site regions, delivering results in 3–4 weeks with 99.9% diagnostic sensitivity—ideal for early targeted therapy and family counselling.
- Consultant Neurologist (Epileptologist) – management of neonatal epilepsy syndromes
- Consultant Neonatologist – acute care and developmental follow‑up of affected newborns
- Clinical Geneticist / Medical Researcher – interpretation of NGS data and familial risk assessment
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Full NGS of KCNQ3 gene (all exons, ±20 bp intronic boundaries) | Single‑gene Sanger sequencing (lower throughput) |
| Diagnostic Sensitivity | 99.9% for point mutations and small indels | ~98% (limited to known mutations) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Types | Whole blood, extracted DNA, or FTA card (one drop) | Whole blood only |
| Reporting | ACMG‑compliant classification + clinical annotation | Basic variant description |
Physician Insight & Safety Protocol
“As a DHA‑licensed Neurologist, I understand how worrying neonatal seizures can be. This genetic test provides clarity and guides precise treatment, but it must always be correlated with the baby’s clinical picture and EEG findings. You are not alone—our team is here to walk you through every result.”
— Dr. Prabhakar Reddy, DHA License: 61713011
Medication Warning:
Do not discontinue any prescribed anti‑seizure medication without consulting your doctor. Sudden withdrawal can precipitate life‑threatening status epilepticus.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent from a legal guardian (mandatory for minors). Unstable clinical condition requiring immediate NICU intervention before genetic sampling.
- Emergency Red Flags – Seek Immediate Medical Attention If: Seizure lasts longer than 5 minutes; baby develops fever, breathing difficulty, or cyanosis; new-onset lethargy or poor feeding after a seizure.
Patient FAQ & Clinical Guidance
1. What is the KCNQ3 gene test and why is it needed for my newborn?
The KCNQ3 gene test uses Next‑Generation Sequencing to detect mutations causing benign neonatal seizures type 2, a condition where babies develop brief, self‑limiting seizures in the first days of life. Identifying the mutation confirms the diagnosis, avoids unnecessary investigations, and enables accurate genetic counselling for future pregnancies.
ما هو تحليل جين KCNQ3 ولماذا يحتاجه طفلي حديث الولادة؟
يكشف تحليل جين KCNQ3 عبر التسلسل من الجيل التالي الطفرات المسببة للنوبات الحميدة الوليدية من النوع الثاني، مما يؤكد التشخيص ويجنب الفحوصات غير الضرورية ويتيح استشارات وراثية دقيقة.
2. How accurate is this DNA test and can it miss a mutation?
With a diagnostic sensitivity of 99.9% for point mutations and small insertions/deletions, the NGS test is exceptionally reliable for the KCNQ3 gene; however, rare deep intronic variants or large deletions may require complementary methods. Our laboratory reports all findings according to ACMG guidelines, and a negative result reduces but does not absolutely exclude the possibility of another genetic epilepsy.
ما مدى دقة هذا الاختبار الجيني وهل يمكن أن يفوّت طفرة؟
تبلغ الحساسية التشخيصية 99.9% للطفرات النقطية والحذف الصغير، مما يجعله موثوقًا للغاية، لكن الطفرات العميقة النادرة قد تتطلب اختبارات تكميلية.
3. Will my insurance cover the 2,800 AED cost for the KCNQ3 test in the UAE?
Many UAE insurance plans, including those under DHA and Thiqa, cover medically indicated genetic testing when pre‑authorized; our team provides direct billing verification via WhatsApp at +971 54 548 8731 before your appointment. In cases of partial coverage, a nominal co‑payment may apply, and we offer flexible payment options.
هل يغطي التأمين تكلفة 2800 درهم لتحليل KCNQ3 في الإمارات؟
تغطي العديد من خطط التأمين في الإمارات الفحص الجيني عند الطلب الطبي بعد الحصول على موافقة مسبقة؛ نتحقق من التغطية عبر واتساب قبل الموعد.
Pre‑ Preparation:
- A genetic counselling session is required to draw a pedigree chart of family members affected with KCNQ3-related seizures.
- Bring clinical history of the patient, including birth records, EEG reports, and medication list.
- Sample collection: blood or one drop of blood on an FTA card (extracted DNA also accepted). No fasting required for the infant.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians